Sanofi offers to buy Dutch biotechnology firm Kiadis for $358.4 million
Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells03-11-2020
03-11-2020
Sanofi India September-quarter net profit at Rs 133 crore
The company had posted a net profit of Rs 126.6 crore in the corresponding period of the previous fiscal, Sanofi India said in a filing to BSE.27-10-2020
Sanofi India Ltd - 500674 - Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2020
We refer to our letter dated 13th October 2020 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 1.30 p.m. and concluded at 4.15 p.m. The Board approved unaudited financial results for the quarter and nine months ended 30th September 2020. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and nine months ended 30th September 2020 approved at this Meeting along with a copy of the Limited Review Report duly signed by the Auditors of the Company. Please take the above information on record.27-10-2020
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.26-10-2020
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed.22-10-2020
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.22-10-2020
Sanofi India Ltd - 500674 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September 2020
Pursuant to Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Certificate of M/s. Makarand M. Joshi & Co., Company Secretaries for the half year ended 30th September 202020-10-2020
Sanofi India Ltd - 500674 - Shareholding for the Period Ended September 30, 2020
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here15-10-2020
Sanofi India Ltd - 500674 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- GIRISH TEKCHANDANIDesignation :- Company Secretary and Compliance Officer15-10-2020
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice of the Board Meeting of the Company published today, in newspapers, Business Standard and Sakal.14-10-2020